Table 3.
Multiple Regression Analyses of Cardiovascular Mortality Without and With Censoring at Time of Salvage GnRH Agonist Therapy (N = 641)
| Covariate | Without Censoring
|
With Censoring
|
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Treatment arm: arm 2 v arm 1 | 0.73 | 0.47 to 1.15 | .16 | 0.99 | 0.58 to 1.69 | .97 |
| Age: < 70 v ≥ 70 years | 1.57 | 0.95 to 2.59 | .08 | 1.39 | 0.79 to 2.45 | .26 |
| Prevalent CVD: no v yes | 2.60 | 1.65 to 4.11 | < .0001 | 2.92 | 1.71 to 4.98 | < .0001 |
| Prevalent HTN: no v yes | 1.32 | 0.85 to 2.04 | .22 | 1.57 | 0.96 to 2.57 | .08 |
| Prevalent DM: no v yes | 2.54 | 1.49 to 4.34 | .0006 | 2.92 | 1.57 to 5.43 | .0007 |
| BMI, kg/m2 | ||||||
| < 25 | — | — | — | — | ||
| ≥ 25 to < 30 | 0.94 | 0.58 to 1.54 | .81 | 0.89 | 0.49 to 1.61 | .70 |
| ≥ 30 | 0.87 | 0.45 to 1.67 | .67 | 0.92 | 0.42 to 2.01 | .83 |
| Race: black v other | 1.25 | 0.60 to 2.59 | .55 | 2.05 | 0.74 to 5.63 | .17 |
| Prostatectomy: no v yes | 0.45 | 0.14 to 1.47 | .18 | 0.33 | 0.09 to 1.28 | .11 |
| Nodal involvement: no v yes | 1.31 | 0.65 to 2.63 | .45 | 0.84 | 0.35 to 2.03 | .70 |
| Acid phosphatase: not elevated v elevated | 1.15 | 0.72 to 1.84 | .57 | 1.26 | 0.73 to 2.19 | .41 |
| Gleason score | ||||||
| 2-6 | — | — | — | — | ||
| 7 | 0.81 | 0.49 to 1.34 | .41 | 0.72 | 0.40 to 1.30 | .28 |
| 8-10 | 0.62 | 0.35 to 1.10 | .10 | 0.55 | 0.28 to 1.11 | .10 |
| Clinical stage: A/B v C | 1.13 | 0.46 to 2.83 | .79 | 0.57 | 0.20 to 1.61 | .29 |
Abbreviations: GnRH, gonadotropin-releasing hormone; HR, hazard ratio; CVD, cardiovascular disease; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index.